What’s next for Hikma Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc.?
Regenerun Pharmaceuticals (HIKMA) has agreed to pay a record $1.4 billion to resolve allegations that it withheld favorable research from investors and misled investors in its two flagship medicines.Regeneronne Pharmaceuticals was also ordered to pay $500 million for misappropriating proprietary technology from Hikma.The two firms are in the midst of negotiations with regulators and the…